Difficulty: Medium
Average Score: 67%
Practice
Triple anti- H-pylori therapy may include all the following drugs except:
Correct answer
C
Rationale
In the context of a pharmacology exam focusing on triple anti-H. pylori therapy, the correct answer is C) Famotidine. This is because triple therapy for H. pylori typically consists of a proton pump inhibitor (PPI) like Lansoprazole to reduce stomach acid, an antibiotic like Clarithromycin to fight the H. pylori bacteria, and another antibiotic or bismuth compound. Famotidine, an H2-receptor antagonist like Ranitidine, is not typically included in the standard triple therapy regimen for eradicating H. pylori.
Ranitidine, Lansoprazole, and Clarithromycin are commonly used in H. pylori treatment. Ranitidine and Lansoprazole are acid-reducing agents that help the antibiotics work more effectively by reducing the acidity of the stomach, creating a better environment for antibiotic action. Clarithromycin is an antibiotic that directly targets the H. pylori bacteria, aiding in its eradication.
In an educational context, understanding the rationale behind the selection of specific drugs in H. pylori treatment is crucial for healthcare professionals. It highlights the importance of combination therapy to target different aspects of the infection, such as acid reduction and bacterial eradication. This knowledge is essential for effective clinical decision-making and ensuring successful treatment outcomes for patients with H. pylori infections.
Ranitidine, Lansoprazole, and Clarithromycin are commonly used in H. pylori treatment. Ranitidine and Lansoprazole are acid-reducing agents that help the antibiotics work more effectively by reducing the acidity of the stomach, creating a better environment for antibiotic action. Clarithromycin is an antibiotic that directly targets the H. pylori bacteria, aiding in its eradication.
In an educational context, understanding the rationale behind the selection of specific drugs in H. pylori treatment is crucial for healthcare professionals. It highlights the importance of combination therapy to target different aspects of the infection, such as acid reduction and bacterial eradication. This knowledge is essential for effective clinical decision-making and ensuring successful treatment outcomes for patients with H. pylori infections.